

MINUTES OF THE 183rd MEETING OF THE REVIEW COMMITTEE ON GENETIC MANIPULATION (RCGM) HELD ON 05.05.2020 BY VIDEO CONFERENCING

The Chairman, RCGM extended a formal welcome to the members of the RCGM for the 183rd meeting and initiated the process of the meeting. The list of participants is given at Annexure-I.

2. The Committee adopted the minutes and recommendations of the 182nd meeting of the RCGM held on 07.04.2020.

3. On action taken report, the Member-Secretary informed that during the 182nd meeting of the RCGM, a total of 28 applications including information items were considered and the Secretariat is in the process of issuing requisite permit letters based on the recommendations of the RCGM.

4. Proposals considered

4.1 Applications in the area of pharmaceuticals

The Committee considered applications to import SARS-CoV-2 virus Hong Kong isolate, SARS-CoV2 virus, eggs of GE *Anopheles Stephensi*, *Plasmodium berghei* chimera strains, reagents to develop influenza and SARS-CoV2 vaccine, recombinant plasmids, recombinant rhabdovirus based vector, recombinant rabies virus, non-pathogenic amplified regions of SARS CoV2 genes; to export recombinant R21 antigen; to receive COVID-19 blood samples, SARS-CoV2 virus, COVID-19 blood samples of recovered individuals, SARS CoV 2 virus strain(s), Nasal & Throat swab from SARS-CoV-2 patients; to conduct preclinical toxicity studies on Hepatitis A and Hepatitis E Vaccine, recombinant Chymosin, Tenecteplase biosimilar, recombinant SARS-CoV 2 vaccine, Trastuzumab biosimilar; pre-clinical toxicity study reports on Adalimumab biosimilar, Denosumab biosimilar, Measles and Rubella Vaccine; to develop hexavalent combination vaccine. After deliberation on each application including information items, appropriate decision was taken by the RCGM.

4.2 Applications in the area of Agriculture

The Committee considered applications to conduct confined field trials for event selection of GE cotton and GE brinjal; report on event selection trial of GE cotton lines. After deliberation on each application, appropriate decision was taken by the RCGM.

5. IBSC Reports


The Committee considered one annual compliance report; appropriate decision was taken by the RCGM.

6. Other items

The Committee considered the draft Checklist and instructions for development of COVID-19 vaccines and applications of gene therapy product and appropriate decision was taken by the RCGM. The Committee also noted the information items.

No other transaction took place and the meeting ended with vote of thanks to the chair.

The Minutes are approved.


(Dr. Rakesh Kumar Mishra)
Chairman, RCGM

List of Participants:

List of Participants:		
1.	Dr. Rakesh Kumar Mishra, Director-CCMB, Hyderabad	Chairman
2.	Dr. Amita Aggarwal, SGPIMS, Lucknow	Co-Chair (Pharma)
3.	Dr. Kuldeep Singh, Director, ICAR- NBPGR, New Delhi	Co-Chair (Agri)
4.	Dr. Gururaj Katti, Principal Scientist & Head, ICAR- IIRR, Hyderabad	Member
5.	Dr. S.K. Rath, Principal Scientist, CSIR- CDRI, Lucknow	Member
6.	Dr. P. V. Mohanan, Scientist 'G', SCTIMST, Thiruvananthapuram	Member
7.	Dr. K.G.Tirumurugaan, Professor, TANUVAS, Chennai	Member
8.	Dr. Pradyumna Kumar Singh, CSIR-National Botanical Research Institute, Lucknow	Member
9.	Dr. Anand Kumar Kondapi, School of Life Science, University of Hyderabad, Hyderabad	Member
10.	Dr. Chandish R. Ballal, Director, National Bureau of Agricultural Insect Resources, Bangalore	Member
11.	Dr. R. Uma Shaanker, Univeristy of Agricultural Sciences, Bengaluru	Member
12.	Dr. Thangarajan Rajkumar, Professor and Head, Cancer Institute, Chennai	Member
13.	Dr. Guhan Jayaraman, Indian Institute of Technology, Madras	Member
14.	Dr. Neelam S. Sangwan, Head, Department of Biochemistry, Central University of Haryana, Mahendergarh	Member
17.	Sh. Tarun Kathula, Director Biosafety, MoEFCC & Member Secretary-GEAC	Nominee-MoEF& CC
18.	Dr. Geeta Jotwani, Scientist F	Nominee-ICMR
19.	Dr. Shilpi Paul, Scientist E, SERB	Nominee-DST
20.	Dr. Alka Sharma, Scientist-G, & Nodal Officer (Biopharma), DBT, New Delhi	Member
21.	Dr. A.K. Rawat, Scientist- G & Nodal Officer (Agri.), DBT, New Delhi	Member
22.	Dr. Vanga Siva Reddy, CSO, BSU, New Delhi	Special Invitee
23.	Dr. Nitin K. Jain, Scientist-F, DBT	Member Secretary
DBT and Biosafety Support Unit :		
24.	Dr. Gandharva Nagpal, Scientist C, DBT	
25.	Dr. Sangeeta Agarwal, Chief (Agriculture), BSU	
26.	Dr. Poonam Vishwakarma, Scientist, BSU	
27.	Dr. Reema Sharma, Scientist, BSU	
28.	Dr. Govind Kumar Rai, Scientist, BSU	
29.	Dr. Manpreet Kaur, Scientist, BSU.	
Others:		
30.	Dr. Rajyashri Ramakarishna, Shilpa Medicare Limited, Hubli	
31.	Mr. Vinay Konaje, Shilpa Medicare Limited, Hubli	
32.	Dr. Saravanan Muthaiah, Vipragen Biosciences Pvt Ltd, Mysuru, Karnataka	
33.	Mr. Hari Prasad Raju P, Cadila Healthcare, Ahmedabad	

34.	Mr. Sanjay Maheshwari, Cadila Healthcare, Ahmedabad
35.	Dr. Chozhavel Rajanathan, Cadila Helathcare, Ahmedabad
36.	Dr. Jitendra Patel, Cadila Healthcare, Ahmedabad
37.	Dr. Raunak Soman, Sanzyme Biologics Pvt. Ltd., Hyderabad
38.	Dr. Malisetty Venkat Swamy, Sanzyme Biologics Pvt. Ltd., Hyderabad
39.	Dr. Madhavi Dandu, Sanzyme Biologics Pvt. Ltd., Hyderabad (to be confirmed)
40.	Dr. Jagan Mohan Reddy, Sanzyme Biologics Pvt. Ltd., Hyderabad
41.	Dr. Anantha Metlakunta, Sanzyme Biologics Pvt. Ltd., Hyderabad
42.	Mr. Nagendra Sibbena, Sanzyme Biologics Pvt. Ltd., Hyderabad
43.	Dr. Bala Reddy, Hetero Drugs limited, Telangana
44.	Mr. Rajendran Reddy, Hetero Drugs limited, Telangana
45.	Mr. Vijay Nag Thota, Hetero Drugs limited, Telangana
46.	Mr. Pradeep Kumar Iyer, Hetero Drugs, Telangana
47.	Dr. Dwarkesh Parihar, Bioseed Research India, a division of DCM Shriram Ltd.
48.	Dr. Nupur Mehrotra, Premas Biotech Pvt. Ltd., Manesar, Haryana
49.	Dr. Prabuddha Kundu, Premas Biotech Pvt. Ltd., Manesar, Haryana
50.	Mr. Gaurav Kaushik, Premas Biotech Pvt. Ltd., Manesar, Haryana
51 .	Dr. Ruchir Rastogi, Premas Biotech Pvt. Ltd., Manesar, Haryana

f